Literature DB >> 16226302

Erythropoietin disrupts hypoxia-inducible factor signaling in ovarian cancer cells.

Sarah A Hale1, Cheung Wong, Karen M Lounsbury.   

Abstract

OBJECTIVE: The objective of this study was to evaluate the effects of recombinant erythropoietin (EPO) on HIF-1alpha induced angiogenic pathways in ovarian cancer cells.
METHODS: Using Western blots and both quantitative and non-quantitative RT-PCR, HIF-1alpha protein and VEGF transcription levels were assessed. Cell growth was measured using flow cytometry.
RESULTS: EPO treatment decreased hypoxia-induced HIF-1alpha protein levels and VEGF transcription, with no effect on cell growth. Inhibition of HIF-1alpha signaling by EPO was also observed in MCF-7 breast cancer cells.
CONCLUSION: These novel findings suggest that EPO may exhibit anti-angiogenic properties, thus encouraging further exploration of signaling pathways between EPO and HIF-1alpha.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16226302     DOI: 10.1016/j.ygyno.2005.08.056

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

Review 1.  Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents.

Authors:  Charles L Bennett; Stephen Y Lai; Michael Henke; Sara E Barnato; James O Armitage; Oliver Sartor
Journal:  Arch Intern Med       Date:  2010-09-13

2.  Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia.

Authors:  Monica Fantacci; Paola Bianciardi; Anna Caretti; Thomas R Coleman; Anthony Cerami; Michael Brines; Michele Samaja
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-07       Impact factor: 11.205

3.  Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities.

Authors:  Thomas R Coleman; Christof Westenfelder; Florian E Tögel; Ying Yang; Zhuma Hu; Leanne Swenson; Henri G D Leuvenink; Rutger J Ploeg; Livius V d'Uscio; Zvonimir S Katusic; Pietro Ghezzi; Adriana Zanetti; Kenneth Kaushansky; Norma E Fox; Anthony Cerami; Michael Brines
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

4.  Safety of intravitreally administered recombinant erythropoietin (an AOS thesis).

Authors:  James C Tsai
Journal:  Trans Am Ophthalmol Soc       Date:  2008

Review 5.  Antiangiogenic therapy for cancer: an update.

Authors:  Belal Al-Husein; Maha Abdalla; Morgan Trepte; David L Deremer; Payaningal R Somanath
Journal:  Pharmacotherapy       Date:  2012-12       Impact factor: 4.705

6.  Recombinant Human erythropoietin reduces viability of MCF-7 breast cancer cells from 3D culture without caspase activation.

Authors:  Hareth Y ShujaaEdin; Nagi A Al-Haj; Abdullah Rasedee; Noorjahan Banu Alitheen; Arifah Abdul Kadir; Chee Wun How; Heshu Sulaiman Rahman; Al-Shwyeh Hussah Abdullah
Journal:  Saudi J Biol Sci       Date:  2021-02-11       Impact factor: 4.219

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.